Overview

As a stakeholder in the health and life sciences industry, you work every day to improve human health and enhance patient care. Our national health and life sciences industry team partners with you to advance your objectives. We understand how changing business models, disruptive technologies and increased data security challenges, among other developments, impact your organization, and we work to help you overcome challenges and seize opportunities in this continuously evolving landscape. Whether we are collaborating with a pharmaceutical or medical device manufacturer to guide a new product through the development and approval life cycle or helping health care providers implement their strategic objectives, we provide business-minded solutions to address your most pressing challenges. Our team handles major strategic transactions; represents clients in high-stakes governmental investigations; negotiates cost-saving outsourcing arrangements, IP licenses, software and AI agreements, and research and collaboration agreements; and executes public policy and government affairs strategies for health care, life sciences and patient advocacy organizations. Our professionals include former in-house counsel at health systems and global pharmaceutical and device companies, former congressional and federal agency health policy specialists, and Department of Justice attorneys.

Insights & Events

Latest

最新 April 2025

Tariff Tactics and National Security: Decoding Section 232’s Role in Shaping Trade Policies

Comment Opportunities Available to Advocate for Exclusions and Limited Applications
6 min read  
Press Release April 2025

Faegre Drinker Welcomes Life Sciences Litigator Tom Pack to California Product Liability & Mass Torts Team

3 min read  
最新 April 2025

DOJ Releases New Key Guidance on Its Data Security Program (DSP)

Substantial Compliance Obligations Related to Certain Foreign Transactions Involving Sensitive Personal and Government Data
16 min read  
发表文章 April 2025

Product Liability and Mass Torts Attorneys Contribute to International Comparative Legal Guides’ ‘Drug and Medical Device Litigation 2025’ Guide

1 min read  
最新 April 2025

Federal Court Strikes Down CMS Nursing Home Staffing Mandate

What’s Next for Operators & Investors?
5 min read  
Press Release April 2025

Faegre Drinker Adds Leading Corporate and M&A Partner Michael Baxter in Philadelphia

2 min read  
最新 April 2025

Laboratory-Developed Tests (LDTs) Do Not Qualify as ‘Devices’ Under the Food, Drug and Cosmetic Act

CMS Regulates Laboratory-Developed Test Services Under the Clinical Laboratory Improvements Amendments (CLIA) of 1988
12 min read  
Speaking Engagement Recap March 25, 2025

AI Governance and Risk Management: Key Considerations and Traps for the Unwary

Complimentary Insurance Seminar
1 min read  
Speaking Engagement Recap March 12, 2025

The Current State of Pediatric Research: Challenges, Opportunities and Action

Society for Pediatric Research Advocacy Committee
1 min read  
Recorded Webinar February 13, 2025 CLE

Inside the FDA Under Trump 2.0 Transition: What We Know & What to Expect From a Career FDA Attorney - Webinar

1 min read  
Insights
最新 April 2025

Tariff Tactics and National Security: Decoding Section 232’s Role in Shaping Trade Policies

Comment Opportunities Available to Advocate for Exclusions and Limited Applications
6 min read  
最新 April 2025

DOJ Releases New Key Guidance on Its Data Security Program (DSP)

Substantial Compliance Obligations Related to Certain Foreign Transactions Involving Sensitive Personal and Government Data
16 min read  
发表文章 April 2025

Product Liability and Mass Torts Attorneys Contribute to International Comparative Legal Guides’ ‘Drug and Medical Device Litigation 2025’ Guide

1 min read  
最新 April 2025

Federal Court Strikes Down CMS Nursing Home Staffing Mandate

What’s Next for Operators & Investors?
5 min read  
最新 April 2025

Laboratory-Developed Tests (LDTs) Do Not Qualify as ‘Devices’ Under the Food, Drug and Cosmetic Act

CMS Regulates Laboratory-Developed Test Services Under the Clinical Laboratory Improvements Amendments (CLIA) of 1988
12 min read  
媒体报道 March 2025

Brian Schnell Shares Legal Trends for Franchisors to Watch in 2025 With Franchise Times

2 min read  
最新 March 2025

The Latest on Pharmaceutical Company-Sponsored Diagnostic Testing Programs

OIG’s Second Favorable Opinion Regarding Free Genetic Testing and Counseling: Advisory Opinion No. 24-12
8 min read  
媒体报道 March 2025

Scott Kosnoff Discusses Virginia AI Bill, Future State AI Legislation With Law360

2 min read  
最新 March 2025

EPA Rolls Back Regulations From Climate Change to ‘Waters of the United States’

PFAS and Superfund Do Not Make the List
4 min read  
最新 March 2025

Amid Deteriorating Budget Picture, Divided Minnesota Legislature Faces Difficult Budget Negotiations

Minnesota Legislative Update
6 min read  

Related Legal Services